linjc16/ctgov huggingface dataset:
Juvenile Essential Arterial Hypertension and Vascular Function

Study Overview
=================
Brief Summary
-----------------
The main goal of this study is to investigate the association of the juvenile essential arterial hypertension with systemic micro- and macrovascular reactivity and cerebral vascular function, and to examine the potential impact of elevated oxidative stress on this associations.

Official Title
-----------------
Juvenile Essential Arterial Hypertension and Vascular Reactivity in Systemic and Cerebral Circulation

Conditions
-----------------
Child, Only, Essential Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy normotensive children and children with essential arterial hypertension Exclusion Criteria: secondary arterial hypertension other systemic diseases with immunopathology neurodegenerative diseasesat children that use therapy which has a high impact on vascular or immunological function (immunotherapy, immunosuppressive therapy, sistemic corticosteroid therapy etc..).

Ages Eligible for Study
-----------------
Minimum Age: 9 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| NT group - normotensive children<br> | |
| HT group - hypertensive children<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Systemic microvascular function in children | Skin microvascular reactivity assessed by Laser Doppler flowmetry (post-occlusive reactive hyperemia, iontophoresis of acetylcholine and sodium nitroprusside) - measured in perfusion units (PU) | Day 1. | 
| Systemic macrovascular function in children | Vascular ultrasound measurement of brachial artery response to vascular occlusion (flow mediated dilation; FMD, %) | Day 1. | 
| Cerabral vascular function in children | Cerebral blood flow velocities assessed by transcranial Doppler sonography (cm/s) | Day 1. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oxidative stress - thiobarbituric acid reactive substances (TBARS) | Serum sample collection for measurement of biomarkers of oxidative stress level. Thiobarbituric acid reactive substances (TBARS) - biomarker of lipid peroxidation. | Day 1. | 
| Endocan | Serum sample collection for ELISA measurement of serum endocan level - proteoglycan associated with endothelium activation | Day 1. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cerebral circulation, endothelium, microcirculation, macrocirculation, hypertension, oxidative stress, child
Dimensional Changes of Free Epithelial Graft at Teeth and Implant Sites

Study Overview
=================
Brief Summary
-----------------
For the management of peridontal and peri-implant conditions, free epithelial grafts have been proposed to provide a sufficient band of keratinized mucosa with the goal of enhancing confort during brushing and reducing the level of inflammation. Nevertheless, these are subjected to dimensional changes that may jeopardise the final outcome of providing sufficient keratinized mucosa to teeth and implants. Hence, this prospective study will aim at shedding light on the dimensional changes and the variables affecting these changes.

Official Title
-----------------
Dimensional Changes of Free Epithelial Graft at Teeth and Implant Sites: A Prospective Clinical Study

Conditions
-----------------
Keratinized Mucosa

Intervention / Treatment
-----------------
* Procedure: Free epithelial (gingival) graft


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients in need of keratinized mucosa to improve the periodontal and peri-implant condition With no uncontrolled disease Non-smokers Exclusion Criteria: Patients with uncontrolled diseases and conditions Smokers Patients with sufficient keratinized mucosa

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: Teeth and implants receiving free epithelial grafts harvested from the palate
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Free epithelial graft<br>Free epithelial graft at implant and teeth sites to increase the band of keratinized mucosa | Procedure: Free epithelial (gingival) graft<br>* 1mm thickness epithelial layer harvested from the palate (1st molar area) is grafted and stabilised at the dental or implant area deficient of keratinized mucosa<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in keratinized mucosa | Area of keratinized mucosa gain | 3 weeks, 3 months, 6 months follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Factor 1 affecting the dimensional changes | Avascular area exposed to the graft (implant/tooth surface) | 3 weeks, 3 months, 6 months | 
| Factor 2 affecting the dimensional changes | Thickness in mm of the graft | 3 weeks, 3 months, 6 months | 
| Factor 3 affecting the dimensional changes | Thickness in mm of the recipient connective tissue | 3 weeks, 3 months, 6 months |
Cerebral Bases of Arithmetics Processing

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to identify neural correlates involved in arthmetics processing in adults and children aged 8 to 14 with normal cognitive function. Brain area will be identified by functional magnetic resonance imaging (IRMf).

Official Title
-----------------
Neural Bases of Arithmetic Processing: MRIf Study in Adults and Children

Conditions
-----------------
Neural Bases of Arithmetic Processing

Intervention / Treatment
-----------------
* Other: neuropsychological testing
* Other: functional magnetic resonance imaging
* Other: simple arithmetic operations


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children aged 8 to 14 with parents' consent adults aged 18 to 24 right-handed affiliated to the French social security Exclusion Criteria: known neurological disorders including epilepsia known psychiatric disorders including Attention Deficit Disorder birth complications needing intensive care central nervous system treatment important hearing disabilities not corrected impaired vision

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 24 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Healthy subjects aged 18 to 24<br>Subjects without neurological or psychiatric history | Other: neuropsychological testing<br> <br> Other: functional magnetic resonance imaging<br> <br> * Other names: IRMf;Other: simple arithmetic operations<br> <br> |
| Experimental: Healthy subjects aged 8 to 11<br>Subjects without neurological or psychiatric history | Other: neuropsychological testing<br> <br> Other: functional magnetic resonance imaging<br> <br> * Other names: IRMf;Other: simple arithmetic operations<br> <br> |
| Experimental: Healthy subjects aged 12 to 14<br>Subjects without neurological or psychiatric history | Other: neuropsychological testing<br> <br> Other: functional magnetic resonance imaging<br> <br> * Other names: IRMf;Other: simple arithmetic operations<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Brain area activity in arithmetic processing will be identified by IRMf | Brain activity is identified by IRMf | up to 60 days after inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Parietal region activity in arithmetic processing will be identified by IRMf | comparison between group aged to 12to 14 and group aged to 8 to 11 | up to 60 days after inclusion |
Gene-Polymorphies in the P2X7 Gene in Patients With Osteoporotic Fractures

Study Overview
=================
Brief Summary
-----------------
We are looking after gene-polymorphies in the p2x7-gene in patient with osteoporotic fractures.

Official Title
-----------------
Gene-Polymorphies in the P2X7 Gene in Patients With Osteoporotic Fractures

Conditions
-----------------
Hip Fracture

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hip fracture, no dementia, low energy fracture Exclusion Criteria: high energy fracture

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hip fracture, epidemiology, genetics, p2x7
Ultra-Violet Fluorescence Bronchial Cancer Location

Study Overview
=================
Brief Summary
-----------------
Diagnose lung cancer at an early stage is crucial for effective treatment. At these early stages, cancer is usually invisible in ambient white light when the endoscopic analysis of the bronchial mucosa. This lining is self-fluorescent at its illumination by blue light. These widely distributed autofluorescence methods detect early mucosal abnormalities. They are very sensitive but not specific to recognize the lung cancer. Thanks to European funding (EURIMUS), a new tool with fluorescent UV light has been developed. The purpose of this preliminary study is to verify the suitability for specific detection of cancerous tissue in Pneumology of this fluorescence method versus histological analysis of the tissue.

Official Title
-----------------
Ultra-Violet Fluorescence Bronchial Cancer Location

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Procedure: Rigid bronchoscopy with ultraviolet transmission
* Other: Biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient affiliated or entitled to a social security scheme Major Patient Patient who signed the informed consent document Patient with a known primary cancer in bronchial level Exclusion Criteria: Pregnant woman Patient with a benign tumor histology Patient with an unknown tumor histology.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: patients with lung cancer<br> | Procedure: Rigid bronchoscopy with ultraviolet transmission<br> <br> Other: Biopsy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ultraviolet fluorescence ratio Iodine360 / Iodine450 | Detection of cancerous tissues and healthy or inflammatory tissues is used to calculate the sensitivity and specificity of the rigid bronchoscopy with UV transmission compared to biopsy (gold standard). | Day 0 | 
| Histology of tissue | The histology give the final diagnosis | Day 0 |
Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this Phase I/II, open-label, dose-escalation study is to evaluate an investigational monoclonal antibody administered as a first-line therapy to patients with acute, Grade II, III, or IV graft-versus-host disease (GVHD). Patients will be eligible for enrollment within 24 hours of beginning standard steroid treatment. The research is being conducted at up to 10 clinical research sites in the US.

Detailed Description
-----------------
A Phase I/II, open-label, dose-escalation pilot study designed to obtain preliminary safety, pharmacokinetic (PK) and efficacy information on visilizumab administered as a first-line therapy to patients with acute, Grade II, III, or IV graft-versus-host disease (GVHD). It is anticipated that up to 34 patients at up to 10 study centers could be eligible for enrollment in this study. Patients will be eligible for enrollment within 24 hours of beginning standard steroid treatment (2 mg/kg of methylprednisolone IV, or 10 mg/kg hydrocortisone IV, per day). Steroids will be rapidly tapered over one week following visilizumab administration.

Official Title
-----------------
A Phase I/II, Open-Label, Dose-Escalation, Pilot Study to Evaluate Safety and Preliminary Efficacy of Visilizumab as Primary Therapy for Acute Graft-Versus-Host Disease After Hematopoietic Cell Transplantation

Conditions
-----------------
Graft vs Host Disease

Intervention / Treatment
-----------------
* Drug: Visilizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Patients who develop Grade II, III, or IV acute GVHD following allogeneic hematopoietic cell transplantation Patients receiving GVHD prophylaxis including cyclosporine or tacrolimus Clinical findings: skin thickening, joint contraction, oral ulceration, diarrhea. Patients with an onset date of acute GVHD that is less than or equal to 100 days posttransplant.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Visilizumab|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Heart Rate Variability and Orthostatic Hypotension in Stroke Patients Evaluated by Intelligent Biosensor System

Study Overview
=================
Brief Summary
-----------------
This research investigated the heart rate variability (HRV) and stroke patients' orthostatic hypotension in hospitalized stroke patients accompanied with dizziness at varied tilting angle controlled by tilting table with intelligent biosensor.

Detailed Description
-----------------
Stroke patients readily accompany with the occurrence of orthostatic hypotension. To earlier predict patients occurring dizziness during the tilt table test, this study utilized a self-developed integrated intelligent biosensor system to assist clinical staff efficiently and immediately assessing stroke patients with orthostatic hypotension. Further purposes were to survey the relationship between the orthostatic hypotension and heart rate variability (HRV) and find the predicted models of orthostatic hypotension.

Official Title
-----------------
Heart Rate Variability and Orthostatic Hypotension in Stroke Patients Evaluated by Intelligent Biosensor System

Conditions
-----------------
Cerebrovascular Accident

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are first time to get stroke. Exclusion Criteria: unstable physiological conditions, serious joint spasticity, use cortisol or calming drugs, other neurological diseases

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Orthostatic hypotension<br>Collection of information of body mass index, modified Ashworth scale, maximal voluntary contraction(MVC), heart rate variability(HRV). Tilt table test was used in this study to identify if the subjects with or without orthostatic hypotension. | |
| Non-orthostatic hypotension<br>Collection of information of body mass index, modified Ashworth scale, maximal voluntary contraction(MVC), heart rate variability(HRV) Tilt table test was used in this study to identify if the subjects with or without orthostatic hypotension. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of Heart Rate Variability (HRV) | measure subject's HRV, every 3 mins during the Tilt table test | Baseline: before Tilt table test, resting position, measure HRV with 3 minutes interval, totally 7 HRVs were measured | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Heart Rate Variability, orthostatic hypotension, stroke, integrated intelligent biosensor system
Genetics of Coronary Artery Disease in Alaskan Natives (GOCADAN)

Study Overview
=================
Brief Summary
-----------------
To document cardiovascular disease and cardiovascular disease risk factors among 1,200 Native Alaskans who are members of approximately 40 families.

Detailed Description
-----------------
BACKGROUND: There are many compelling reasons to study heart disease in the Native Alaskans. These Eskimo villages are remote and isolated. The traditional lifestyle is being eroded by mechanization and a westernized diet. There has been relatively little outside genetic influence and they are, like the American Indians of the lower 48 states, beginning to show a marked acceleration in the prevalence of atherosclerosis and coronary artery disease. DESIGN NARRATIVE: The study is a family-based, cross sectional study. Recognized and emerging risk factors and prevalent cardiovascular disease are documented in each individual through a standardized interview, physical exam, laboratory measurements, carotid ultrasound, ECG, and a review of centralized medical records. Assays will be made of contemporary samples and serum specimens stored at the Anchorage Center CDC antedating this study (10 to 20 years ago) for specific markers of inflammation and serologic responses. Through a ten-centimorgan genetic map, attempts will be made to find specific genes that relate to cardiovascular disease. The study uses standard methods to assess risk factors relating to lipid metabolism, hypertension, and diabetes mellitus. Importantly, the study also uses state-of-the-art methods for detection of infectious disease exposure, specifically to C. pneumoniae, cytomegalovirus, and other infectious agents hypothesized to play a role in atherogenesis. A case-control age-matched design is used to analyze the infectious disease burden.

Conditions
-----------------
Heart Diseases, Cardiovascular Diseases, Atherosclerosis, Hypertension, Diabetes Mellitus, Coronary Arteriosclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Prevalence of Hypertension Using Telemedical Home Blood Pressure Measurements

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the prevalence of hypertension among citizens of Holstebro, Denmark aged 55-64 years, including both the well treated, the untreated and the insufficiently treated, and to estimate the prevalence of white coat and masked hypertension using home blood pressure measurements with telemedical data transmission.

Official Title
-----------------
Prevalence of Hypertension Using Telemedical Home Blood Pressure Measurements

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Other: Telemedical home blood pressure measurements


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 55 to 64 years Registered address in the municipality of Holstebro Enrolment at a practice of one of the GPs who had agreed to participate in the study. Exclusion Criteria: Unwillingness to participate Incapability to do home blood pressure measurements

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Telemedical home blood pressure measurements|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Office blood pressure |  | 10 minuttes | 
| Telemedical home blood pressure |  | 3 days |